1. Preclinical studies for a retinoschisis clinical trial: We have evaluated 5 new retinoschisin vector and have identified one that shows good efficacy in mouse models at a 10-fold lower dose than our previous clinical candidate. We have completed a preclinical efficacy study with this vector. We also completed preclinical toxicity and biodistribution studies in rabbits examining a broad dose range. The vector was well tolerated in rabbits at scaled doses that correspond to doses that show efficacy in the retinoschisis mouse model. We are now preparing for a GLP toxicity study. 2. Retinitis Pigmentosa due to: RPGR mutation: Full length human and mouse RPGR vectors have been constructed and produced. Genetic manipulation of the intact authentic RPGR exon ORF15 (required for this construct) has not been achieved by most/all other groups Im aware of. The vectors are being evaluated in 2 animal models of RPGR mutation for preclinical efficacy studies. These 2 models are rather slow to develop pathology. Faster models are being developed. RP2: Vector has been produced and is being tested in preclinical efficacy models. 3. CEP290: Vectors have been prepared for this project and are being tested in vivo for expression and efficacy. This project has been expanded to examine several strategies for vector construction. The problem is that the CEP290 gene is 7.4 kb in length and AAV vectors can only package about 5 kb. We are evaluating lentiviral vectors and compacted DNA particles as potential alternative gene transfer vehicles. These studies are ongoing. 4. Improved therapeutics for neovascular diseases: In collaboration with Dr. Carmen Clapp of the Universidad Nacional Autonoma de Mexico, Juriquilla campus, we are examining a novel anti-angiogenic fragment of prolactin, called vasoinhibin, in the context of AAV vectors. AAV vectors encoding vasoinhibin, prolactin, and sFlt-1 (a soluble VEGF receptor fragment that acts as a competitive inhibitor) have been produced and have been tested in an animal model of diabetic retinopathy. These studies have been successful. A manuscript has been submitted and is currently under review. 5. We are screening for capsids with balanced rod/cone transduction properties. These studies are ongoing.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAEY000443-05
Application #
8339781
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2011
Total Cost
$295,003
Indirect Cost
Name
U.S. National Eye Institute
Department
Type
DUNS #
City
State
Country
Zip Code
Sajgo, Szilard; Ghinia, Miruna Georgiana; Brooks, Matthew et al. (2017) Molecular codes for cell type specification in Brn3 retinal ganglion cells. Proc Natl Acad Sci U S A 114:E3974-E3983
Ye, Lei; Kan, Fangming; Yan, Tao et al. (2017) Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-? in HBV-persistent mice. Sci Rep 7:3860
Somasundaram, Preethi; Wyrick, Glenn R; Fernandez, Diego Carlos et al. (2017) C-terminal phosphorylation regulates the kinetics of a subset of melanopsin-mediated behaviors in mice. Proc Natl Acad Sci U S A 114:2741-2746
Zhu, Wan; Shen, Fanxia; Mao, Lei et al. (2017) Soluble FLT1 Gene Therapy Alleviates Brain Arteriovenous Malformation Severity. Stroke 48:1420-1423
Yu, Wenhan; Mookherjee, Suddhasil; Chaitankar, Vijender et al. (2017) Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice. Nat Commun 8:14716
Hanke-Gogokhia, Christin; Wu, Zhijian; Gerstner, Cecilia D et al. (2016) Arf-like Protein 3 (ARL3) Regulates Protein Trafficking and Ciliogenesis in Mouse Photoreceptors. J Biol Chem 291:7142-55
Zeng, Yong; Petralia, Ronald S; Vijayasarathy, Camasamudram et al. (2016) Retinal Structure and Gene Therapy Outcome in Retinoschisin-Deficient Mice Assessed by Spectral-Domain Optical Coherence Tomography. Invest Ophthalmol Vis Sci 57:OCT277-87
Sun, Xun; Park, James H; Gumerson, Jessica et al. (2016) Loss of RPGR glutamylation underlies the pathogenic mechanism of retinal dystrophy caused by TTLL5 mutations. Proc Natl Acad Sci U S A 113:E2925-34
Song, Hongman; Vijayasarathy, Camasamudram; Zeng, Yong et al. (2016) NADPH Oxidase Contributes to Photoreceptor Degeneration in Constitutively Active RAC1 Mice. Invest Ophthalmol Vis Sci 57:2864-75
Díaz-Lezama, Nundehui; Wu, Zhijian; Adán-Castro, Elva et al. (2016) Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1. Lab Invest 96:283-95

Showing the most recent 10 out of 25 publications